Canine
Update (June 10, 2026): Bedinvetmab Non-Inferior to Grapiprant for Canine OA Pain on Force-Plate Gait Analysis
TL;DR
A February 2026 randomized, double-blind non-inferiority trial using objective force-plate gait analysis found bedinvetmab non-inferior to grapiprant for osteoarthritis pain in dogs, supporting both as appropriate first-line options.
What just dropped
Enomoto and colleagues published "A noninferiority trial evaluating the efficacy of bedinvetmab compared to grapiprant for osteoarthritis-pain in dogs using force plate gait analysis" in Scientific Reports (February 2026; PMID 41667566; DOI 10.1038/s41598-026-37626-4). The study, from the Translational Research in Pain Program at North Carolina State University with co-authors including B. Duncan X. Lascelles, is the first head-to-head efficacy comparison of these two widely used canine osteoarthritis (OA) analgesics using objective force-plate gait analysis (FPGA).
- Thirty-two dogs (greater than 20 kg, at least 1 year old) with OA limited to hips and/or stifles were randomized 1:1 to monthly subcutaneous bedinvetmab (plus oral placebo) or daily oral grapiprant (plus monthly saline injection).
- FPGA treatment success rate at day 42 was 68.8 percent for bedinvetmab versus 56.3 percent for grapiprant, a difference of 12.5 percent (90 percent confidence interval -37.5 to 18.8).
- Because the upper bound of that interval (18.8 percent) was below the pre-specified non-inferiority margin of 21.25 percent, bedinvetmab was concluded to be non-inferior to grapiprant.
- Both treatments significantly improved pain and associated clinical signs on client-reported outcome measures, and adverse events were in line with respective label expectations.
Context
Bedinvetmab (Librela/Beransa) is an anti-nerve growth factor monoclonal antibody given by monthly injection, while grapiprant (Galliprant) is an oral EP4-receptor antagonist taken daily. Both target distinct nodes in the OA pain pathway, and clinicians frequently weigh them against each other when choosing a first-line agent. Until now, most evidence came from separate placebo-controlled trials rather than direct comparison. A 2026 overview of veterinary OA treatment (Quintao et al.; PMID 42130714) frames the modern toolkit as spanning COX inhibitors, PGE2/EP4 receptor blockers, chondroprotective agents and biologicals such as anti-NGF antibodies, reflecting how these mechanisms now coexist in practice.
This trial adds objective, force-plate-based evidence to that comparison rather than relying solely on owner questionnaires, which strengthens the interpretation that the two agents deliver comparable analgesia in this population.
What this changes in the Bedinvetmab (Librela) and Grapiprant (Galliprant) evergreens
The bedinvetmab adverse-events page (https://www.thevoyage.ai/forvets/knowledge/bedinvetmab-librela-adverse-events-dogs) and the grapiprant osteoarthritis page (https://www.thevoyage.ai/forvets/knowledge/grapiprant-canine-osteoarthritis-pain) each summarise single-agent efficacy and safety. This non-inferiority trial provides the first objective head-to-head efficacy signal between the two: in dogs with hip/stifle OA, FPGA success rates were 68.8 percent (bedinvetmab) and 56.3 percent (grapiprant), and the formal analysis concluded non-inferiority. The authors state the data support both bedinvetmab and grapiprant as appropriate first-line treatments for OA pain in dogs. Adverse events tracked with each product's label, so the choice between them can hinge on practical factors - injection cadence versus daily oral dosing, owner compliance, and patient-specific contraindications - rather than a large efficacy gap. The study is small (32 dogs) and restricted to hip/stifle OA, so findings should be read as supportive rather than definitive.
References
- Enomoto M, Buslinger L, Thonen-Fleck C, et al. A noninferiority trial evaluating the efficacy of bedinvetmab compared to grapiprant for osteoarthritis-pain in dogs using force plate gait analysis. Sci Rep. 2026;16(1):8986. https://pubmed.ncbi.nlm.nih.gov/41667566/
- Quintao NLM, Moffa EB, Kroier M, et al. Overview of the Current Osteoarthritis Treatment in Veterinary Medicine and Future Directions. ACS Pharmacol Transl Sci. 2026;9(5):1037-1054. https://pubmed.ncbi.nlm.nih.gov/42130714/
Voyage Clinical Desk
From clinical question to SOAP draft - cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.
Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=update-2026-06-10-bedinvetmab-grapiprant-noninferiority
Changelog
- 2026-06-10: First published.
Related reads
References
More clinical updates
Update (June 10, 2026): No Evidence of Circulating RAAS Activation in Cats with Non-Hypertensive CKD or Untreated Hypertension
A May 2026 JVIM study measuring circulating RAAS peptides in cats found no evidence of classical RAAS activation in non-hypertensive CKD or untreated hypertension, refining the rationale for RAAS-targeted therapy.
Read →Update (June 10, 2026): Oclacitinib Resolves Canine Reactive Histiocytosis in a 10-Dog Case Series
A 2026 Vet Dermatol case series of 10 dogs found oclacitinib monotherapy rapidly resolved reactive histiocytosis, including cases refractory to other immunomodulators - an emerging off-label use.
Read →Update (June 10, 2026): 2026 Review Maps the Modern Canine Atopic Dermatitis Treatment Toolkit
An April 2026 review maps the current canine atopic dermatitis toolkit - glucocorticoids, cyclosporine, JAK inhibitors, lokivetmab and immunotherapy - reinforcing a multimodal, individualised approach.
Read →Lokivetmab (Cytopoint) for Canine Atopic Dermatitis: IL-31 Targeting and Clinical Evidence
Lokivetmab (Cytopoint) neutralizes IL-31 to control pruritus in canine atopic dermatitis. Evidence from pivotal RCTs, a 12-month cohort, and combination therapy data reviewed.
Read →